O
ALIM

OrbiMed’s Alimera Sciences ALIM Stock Holding History

OrbiMed’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-13,333
Closed -$484K – 145
2015
Q4 		$484K Hold
13,333
– – ﹤0.01% 129
2015
Q3 		$442K Buy
+13,333
New +$751K ﹤0.01% 132

Other funds holding ALIM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

OrbiMed's ALIM Position: Q1 2019 in Review

OrbiMed sold out of Alimera Sciences (ALIM) in Q1 2019, closing a stake of 16,667 shares — an estimated $180K sold.

OrbiMed first reported a position in ALIM in Q1 2014 and held it in 20 quarters. The position peaked at $11.8M in Q1 2014. 39 funds tracked by Wall St. Rank hold ALIM as of Q1 2019.

  • OrbiMed reported no remaining Alimera Sciences position as of Q1 2019 after selling out during the quarter.
  • OrbiMed sold 16,667 Alimera Sciences shares in Q1 2019, an estimated $180K.
  • OrbiMed first reported a position in Alimera Sciences in Q1 2014 and held it in 20 quarters.
  • OrbiMed's Alimera Sciences position peaked at $11.8M in Q1 2014.
  • 39 funds tracked by Wall St. Rank held Alimera Sciences as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.